Licensed Compounds and Licensed Products Clause Samples
The 'Licensed Compounds and Licensed Products' clause defines which specific chemical compounds and resulting products are covered under a licensing agreement. It typically outlines the scope by listing or describing the compounds, their derivatives, or products that incorporate them, and may specify their intended uses or fields of application. This clause ensures both parties are clear on what substances and products are included in the license, thereby preventing disputes over the rights granted and helping to allocate commercial and development risks appropriately.
Licensed Compounds and Licensed Products. EISAI hereby grants to EPIZYME (a) an exclusive right and license (even as to EISAI and its Affiliates), with the right to grant sublicenses (subject to Section 5.2.2), under the EISAI IP, the EISAI Collaboration IP and EISAI’s interest in the Joint IP, to obtain and maintain Regulatory Approvals for, use, offer for sale, sell, import and otherwise Commercialize (but excluding Manufacturing) Licensed Compounds and Licensed Products in the Field in the EPIZYME Territory, (b) a non-exclusive right and license, with the right to grant sublicenses (subject to Section 5.2.2), under the EISAI IP, the EISAI Collaboration IP and EISAI’s interest in the Joint IP, to conduct and have conducted global Development activities and to Manufacture and have Manufactured Licensed Compounds and Licensed Products anywhere in the world solely for purposes of exercising the rights and licenses granted in the foregoing clause (a), and (c) a non-exclusive right and license, with the right to grant sublicenses (subject to Section 5.2.2), under the EISAI IP, the EISAI Collaboration IP and EISAI’s interest in the Joint IP, to Manufacture and have Manufactured Licensed Compounds and Licensed Products anywhere in the world solely for the supply thereof to EISAI in the EISAI Territory as set forth in Section 3.3.
Licensed Compounds and Licensed Products. EPIZYME hereby grants to EISAI (a) an exclusive right and license (even as to EPIZYME and its Affiliates), with the right to grant sublicenses (subject to Section 5.1.2), under the EPIZYME IP, the EPIZYME Collaboration IP, and EPIZYME’s interest in the Joint IP, to obtain and maintain Regulatory Approvals for, use, offer for sale, sell, import and otherwise Commercialize (but excluding Manufacturing) Licensed Compounds and Licensed Products in the Field in the EISAI Territory and (b) a non-exclusive right and license, with the right to grant sublicenses (subject to Section 5.1.2), under the EPIZYME IP, the EPIZYME Collaboration IP, and EPIZYME’s interest in the Joint IP, to conduct and have conducted Japan-Specific Development Activities and (if EISAI elects to assume Manufacturing responsibilities as set forth in Section 3.3.2) to Manufacture and have Manufactured Licensed Compounds and Licensed Products anywhere in the world solely for purposes of exercising the rights and licenses granted in the foregoing clause (a).
Licensed Compounds and Licensed Products. During the Term Pliant and its Affiliates will not, and will cause its licensees, and sublicensees not to, alone or with or through any Third Parties (including through licensing any Third Party), Research, Develop, Manufacture, or Commercialize anywhere in the Territory (i) a Licensed Compound or Licensed Product; [***] in each case other than Researching, Developing, or Manufacturing Licensed Compounds or Licensed Products in accordance with the terms and conditions of this Agreement.